Concepedia

Rajinder Singh

RS

Statistics

Publications

11

Citations

1.5K

H-Index

10

Active since

2006

Affiliations

Rigel (United States)(Current)

Sunesis (United States)

Post Graduate Institute of Medical Education and Research

Rajinder Singh is an author at Rigel (United States) specializing in medicine, tumor biology, and signal transduction.

ORCID

Top concepts

Publications per year

2006–2022

11

Publications

11

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

Sacha J. Holland, Alison Pan, Christian Franci et al. · Cancer Research · 2010 · 542 citations · Full text

R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

Sylvia Braselmann, Vanessa Taylor, H. Zhao et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 508 citations

Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors

Rajinder Singh, Esteban S. Masuda, Donald G. Payan · Journal of Medicinal Chemistry · 2012 · 99 citations · Full text

, , +13

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

Alvarez Hector, Elizabeth A. Montgomery, Collins Karikari et al. · Cancer Biology & Therapy · 2010 · 90 citations · Full text

, , +11

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

David J. Sweeny, Weiqun Li, Jeffrey Clough et al. · Drug Metabolism and Disposition · 2010 · 89 citations

Rows per page

1–5 of 11